[HTML][HTML] Dipeptidyl-peptidase-IV inhibitors, imigliptin and alogliptin, improve beta-cell function in type 2 diabetes
X Liu, Y Liu, H Liu, H Li, J Yang, P Hu… - Frontiers in …, 2021 - frontiersin.org
Objects Imigliptin is a novel dipeptidyl peptidase-4 inhibitor. In the present study, we aimed
to evaluate the effects of imigliptin and alogliptin on insulin resistance and beta-cell function …
to evaluate the effects of imigliptin and alogliptin on insulin resistance and beta-cell function …
Dipeptidyl-Peptidase-IV Inhibitors, Imigliptin and Alogliptin, Improve Beta-Cell Function in Type 2 Diabetes.
X Liu, Y Liu, H Liu, H Li, J Yang, P Hu… - Frontiers in …, 2021 - europepmc.org
Methods A total of 37 Chinese T2DM patients were randomized to receive 25 mg imigliptin,
50 mg imigliptin, placebo, and 25 mg alogliptin (positive drug) for 13 days. Oral glucose …
50 mg imigliptin, placebo, and 25 mg alogliptin (positive drug) for 13 days. Oral glucose …
Dipeptidyl-Peptidase-IV Inhibitors, Imigliptin and Alogliptin, Improve Beta-Cell Function in Type 2 Diabetes
X Liu, Y Liu, H Liu, H Li, J Yang, P Hu, X Xiao, D Liu - 2021 - pubmed.ncbi.nlm.nih.gov
Objects Imigliptin is a novel dipeptidyl peptidase-4 inhibitor. In the present study, we aimed
to evaluate the effects of imigliptin and alogliptin on insulin resistance and beta-cell function …
to evaluate the effects of imigliptin and alogliptin on insulin resistance and beta-cell function …
[HTML][HTML] Dipeptidyl-Peptidase-IV Inhibitors, Imigliptin and Alogliptin, Improve Beta-Cell Function in Type 2 Diabetes
X Liu, Y Liu, H Liu, H Li, J Yang, P Hu… - Frontiers in …, 2021 - ncbi.nlm.nih.gov
Methods A total of 37 Chinese T2DM patients were randomized to receive 25 mg imigliptin,
50 mg imigliptin, placebo, and 25 mg alogliptin (positive drug) for 13 days. Oral glucose …
50 mg imigliptin, placebo, and 25 mg alogliptin (positive drug) for 13 days. Oral glucose …